Merit Medical Systems Company Profile (NASDAQ:MMSI)

Merit Medical Systems trades on the NASDAQ under the ticker symbol "MMSI."

Merit Medical Systems, Inc. (NASDAQ:MMSI) announced its quarterly earnings results on Thursday, April, 27th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.05. The business earned $171.07 million during the quarter, compared to analysts' expectations of $163.50 million. Merit Medical Systems had a net margin of 4.80% and a return on equity of 9.36%. The business's revenue for the quarter was up 23.9% on a year-over-year basis. During the same period last year, the business earned $0.19 earnings per share. View Merit Medical Systems' Earnings History.

Merit Medical Systems updated its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $1.15-1.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.12. The company issued revenue guidance of $713-723 million, compared to the consensus revenue estimate of $715.66 million.

9 equities research analysts have issued 1-year price targets for Merit Medical Systems' shares. Their forecasts range from $20.00 to $46.00. On average, they expect Merit Medical Systems' share price to reach $37.09 in the next twelve months. View Analyst Ratings for Merit Medical Systems.

Here are some recent quotes from research analysts about Merit Medical Systems stock:

• 1. According to Zacks Investment Research, "Merit Medical Systems, Inc. was formed for the purpose of producing single-use medical products of high quality and superior value primarily for use in diagnosis and treatment of cardiovascular disease. The company's products are designed to provide physicians and other health care professionals with devices that enable them to perform interventional and diagnostic procedures safely and effectively. " (6/22/2017)
• 2. Canaccord Genuity analysts commented, "We maintain our Buy rating on shares of MMSI but lower, albeit modestly, our price target from $35 to $33.50 due to modest dilution to our forward EPS targets from the recently completed secondary offering. To wit, the company completed a public offering of 4,500,000 shares of common stock at a price of $28.25 per share last Wednesday. The company raised nearly $125M in order to pay down some of its outstanding long term debt, which stood at $314M as of year-end 2016, including $180M revolving credit loans outstanding, not including an additional $38M of revolving credit loans to finance the Catheter connections purchase in early 1Q17. We see the secondary offering as prudent and necessary in order to remain at required leverage ratios. In short, we retain our thesis that stronger top-line revenue growth and expanding gross margins should continue to drive double-digit earnings growth – notwithstanding the offering dilution to share count – for the next few years at least." (3/27/2017)

Some companies that are related to Merit Medical Systems include Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ELEKTA (EKTAY), ACADIA Pharmaceuticals (ACAD), Opko Health (OPK), Nektar Therapeutics (NKTR), ICU Medical (ICUI), Chemed Corp. (CHE), Intercept Pharmaceuticals (ICPT), Cantel Medical Corp. (CMD), Juno Therapeutics (JUNO), Sage Therapeutics (SAGE), Globus Medical (GMED), BeiGene (BGNE), INC Research Holdings (INCR), Insulet Corporation (PODD), Ultragenyx Pharmaceutical (RARE) and LivaNova PLC (LIVN).

Merit Medical Systems' management team includes the folowing people:

• Fred P. Lampropoulos, Chairman of the Board, President, Chief Executive Officer
• Bernard J. Birkett, Chief Financial Officer, Treasurer
• Joseph C. Wright, President - International Division
• Ronald A. Frost, Chief Operating Officer
• Justin J. Lampropoulos, Executive Vice President - Sales, Marketing and Strategy
• Brian G. Lloyd, Chief Legal Officer, Corporate Secretary
• Nolan E. Karras, Lead Independent Director
• David Ming-Teh Liu, Director
• Kent W. Stanger, Director
• A. Scott Anderson, Independent Director

Merit Medical Systems' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (1.49%), Dalton Greiner Hartman Maher & Co. (0.98%), AMI Asset Management Corp (0.84%), Thomson Horstmann & Bryant Inc. (0.64%), Peregrine Capital Management LLC (0.63%) and Fisher Asset Management LLC (0.32%). Company insiders that own Merit Medical Systems stock include A Scott Anderson, F Ann Millner, Franklin J Miller, Kent W Stanger, Michael E Stillabower, Nolan E Karras and Richard W Edelman. View Institutional Ownership Trends for Merit Medical Systems.

Merit Medical Systems' stock was sold by a variety of institutional investors in the last quarter, including Thomson Horstmann & Bryant Inc., Capital Impact Advisors LLC, Dalton Greiner Hartman Maher & Co., Capstone Asset Management Co. and US Bancorp DE. Company insiders that have sold Merit Medical Systems stock in the last year include A Scott Anderson, F Ann Millner, Franklin J Miller, Kent W Stanger, Michael E Stillabower, Nolan E Karras and Richard W Edelman. View Insider Buying and Selling for Merit Medical Systems.

Merit Medical Systems' stock was acquired by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Bank of Montreal Can, Fisher Asset Management LLC, Rockefeller Financial Services Inc., Fox Run Management L.L.C., Atria Investments LLC, Peregrine Capital Management LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Merit Medical Systems.

Shares of Merit Medical Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Merit Medical Systems stock can currently be purchased for approximately $38.25.